Chinese billionaire behind Hansoh Pharmaceutical enriched as Hang Seng Index review fuels rally among new elite members
- Chairwoman and CEO Zhong Huijuan and her Cambridge-trained daughter control 66 per cent of the Shanghai-based pharma group
- Three other new index members – Baidu, Chow Tai Fook Jewellery and China Shenhua Energy – will also join from September 5
The Shanghai-based group has a market capitalisation of HK$94.8 billion, having lost 16 per cent or HK$17.8 billion this year. The stock crashed 49 per cent in 2021, erasing HK$110 billion of value.
Ranked among mainland China’s top three drug makers, Hansoh Pharmaceutical was founded in 1995 by Zhong Huijuan, its 61-year old chairwoman and chief executive officer. Together with her Cambridge-trained daughter Sun Yuan, the family controls 66 per cent of the group, according to its annual report.
Zhong is credited with a US$8.2 billion fortune by Forbes, while her spouse Sun Piaoyang separately controls about a quarter of Shanghai-listed Jiangsu Hengrui Medicine Co. Developer Country Garden’s Yang Huiyan topped the list of women billionaires with US$18.7 billion.
Three other stocks, selected by index compiler Hang Seng Indexes Company, also advanced. Baidu, China’s biggest search-engine operator, added 0.9 per cent to HK$128.90 while state-controlled coal mining group China Shenhua Energy added 2.1 per cent to HK$24. Chow Tai Fook Jewellery Group surrendered gain, slipping 0.6 per cent to HK$16.26.